touchPODCAST

Continuous glucose monitoring for cardiovascular risk reduction: The next frontier in preventive care

touchEXPERT FOCUS for touchCARDIO and touchENDOCRINOLOGY

Listen to two experts discuss how continuous glucose monitoring (CGM) can help identify and manage cardiovascular risk in people with or without diabetes. They explore the role of glycaemic variability, the limitations of conventional glucose metrics, and the added value of CGM, including recent advances and patient education to support effective use.

The experts:

• Dr Eden Miller, Diabetes and Obesity Care, Bend, OR, USA
• Dr Ian J Neeland, Case Western Reserve University, and Harrington Heart and Vascular Institute, University Hospitals Cleveland, OH, USA

This activity is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from Abbott Diabetes Care Inc.

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.

For further information visit our website: www.touchCARDIO.com and www.touchENDOCRINOLOGY.com

HER2 as a targetable biomarker in gastrointestinal oncology

touchEXPERT FOCUS for touchONCOLOGY

Listen to a series of short interviews with three leading experts as they discuss the use of HER2 as a targetable biomarker in gastrointestinal oncology. The faculty cover the clinical significance of HER2 alterations, best practices for biomarker testing, key clinical trial data on efficacy and safety, and the role of HER2-targeted therapies in both common and rare GI cancers. They also address retesting at progression, management of adverse events, and emerging treatment approaches.

The experts

• Dr Yelena Janjigian, Memorial Sloan Kettering Cancer Center, New York, NY, USA
• Prof. Eric Van Cutsem, University of Leuven, Leuven, Belgium
• Prof. Florian Lordick, University of Leipzig, Leipzig, Germany

This touchPODCAST is for HCPs outside of the UK

This activity is funded by an independent medical education grant from AstraZeneca. 

This activity is jointly provided by USF Health and touchIME. 
touchIME is an EBAC® accredited provider. 

For further information visit our website: 
www.touchONCOLOGY.com 

Navigating the evolving role of immunotherapy in advanced endometrial carcinoma

touchPANEL DISCUSSION for touchONCOLOGY

Listen to three leading international experts in gynaecological oncology as they discuss how immunotherapy is transforming the treatment of advanced endometrial carcinoma. The faculty explore how the latest data are shaping first-line treatment decisions, how to personalize therapy using biomarkers and molecular classification, and how to manage immune-related adverse events through practical monitoring strategies.

The experts

• Prof. Isabelle Ray-Coquard, Centre Léon Bérard, Lyon, France
• Prof. Nicoletta Colombo, University of Milan-Bicocca, Milan, Italy
• Dr Brian Slomovitz, Mount Sinai Medical Center, Miami, FL, USA

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC.

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchoncologyime.org/panel-icis-in-ec/ 

Focus on treatment advances for ATTRv: A heterogeneous, highly debilitating and ultimately fatal disease

touchEXPERT FOCUS for touchNEUROLOGY and touchCARDIO

Listen to Dr Chafic Karam share expert insights on diagnosing and managing ATTRv amyloidosis. In this short interview, he covers red-flag symptoms, diagnostic challenges and key strategies for differentiating ATTRv. He also discusses current treatment options, including TTR stabilisers and gene silencers, as well as emerging therapies aimed at improving patient outcomes.

The expert:

• Dr Chafic Karam, University of Pennsylvania, Philadelphia, PA, USA

This touchPODCAST is for HCPs in the USA only.

This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our websites: 

https://touchneurology.com/ and https://touchcardio.com/

Navigating the treatment of RRMM with BCMA-directed therapies: Updates from COMy, ASCO and EHA 2025

touchCONGRESS for touchHAEMATOLOGY and touchONCOLOGY

Listen to multiple myeloma expert Prof. Philippe Moreau review key data for BCMA-targeting agents in the treatment of relapsed/refractory multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy), American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) 2025 congresses. Prof. Moreau is then joined by fellow experts Dr Paola Neri and Prof. Hermann Einsele to discuss how these data may apply in clinical practice.

Overview

• Data reviews with Prof. Moreau
• Expert panel discussions with Prof. Moreau, Dr Neri and Prof. Einsele on the themes below

Clinical themes

• Approved BCMA-directed therapeutic approaches 
• Practical application of BCMA-directed therapies
• Future of treating RRMM: Emerging BCMA-directed therapies and combinations

The internationally renowned multiple myeloma expert faculty

• Prof. Philippe Moreau: Nantes, France

• Prof. Hermann Einsele: Würzburg, Germany

• Dr Paola Neri: Calgary, AB, Canada

This touchPODCAST is for HCPs outside of the USA. 

This activity is funded by an independent medical education grant from GSK.

This activity is provided by touchIME.
touchIME is an EBAC® accredited provider.

For further information, visit our website: www.touchHAEMATOLOGY.com and www.touchONCOLOGY.com

Advancing care for patients with infantile haemangiomas: Timing is key

touchEXPERT FOCUS for touchDERMATOLOGY

Listen to Prof. Ilona Frieden share expert insights on the clinical management of infantile haemangiomas, with a focus on timely referral and effective risk stratification. She also explores current and emerging treatment options and practical strategies to support families throughout a patient’s care journey. 

The expert:

• Prof. Ilona Frieden, University of California, San Francisco, CA, USA

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Pierre Fabre Pharmaceuticals, Inc.

This activity is jointly provided by USF Health and touchIME in collaboration with our education partner, Pediatric Dermatology Research Alliance (PeDRA).

For further information visit our website:

https://touchdermaime.org/

Incorporating ADCs into the treatment of mBC: Practical considerations for the community oncologist

touchIN CONVERSATION for touchONCOLOGY

Listen to two oncologists discuss the incorporation of antibody–drug conjugates (ADCs) into the treatment of metastatic breast cancer, tackling questions submitted by the oncology community. They discuss how treatment can be guided by biomarkers, give practical insights into creating a personalized care plan for patients, and share strategies for managing ADC-associated toxicities.

The experts

• Prof. Giuseppe Curigliano, European Institute of Oncology and University of Milan, Italy
• Dr Alison Conlin, Providence Cancer Institute, Portland, OR, USA

This touchPODCAST is for HCPs outside of the UK. 

This activity is funded by an independent medical education grant from Gilead Sciences, Inc.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information, visit our website: https://touchoncologyime.org/adcs-in-the-treatment-of-mbc/

 

Multidisciplinary management of TNBC Integrating immunotherapies for early and metastatic disease

touchEXPERT FOCUS for touchONCOLOGY

Listen to a series of short interviews with three leading experts discussing the application of immunotherapy in triple-negative breast cancer (TNBC). The experts explore the latest data and guideline recommendations for immunotherapy in early-stage and metastatic TNBC, and how to maximize treatment benefits. 

The experts:

• Prof. Sherko Kümmel – Kliniken Essen-Mitte, Essen, Germany
• Prof. Rebecca Dent – National Cancer Center Singapore, Singapore
• Prof. Peter Schmid – Barts Cancer Institute, London, UK

This touchPODCAST is for healthcare professionals outside of the UK.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. 

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website:

https://touchoncologyime.org/management-of-tnbc-with-immunotherapy/

Applying immunotherapy in clinical practice for patients with early-stage NSCLC

touchEXPERT FOCUS for touchRESPIRATORY

Listen to Prof. Jonathan Spicer share expert insights on immunotherapy in early-stage non-small cell lung cancer (NSCLC). He explores current treatment strategies, highlights the role of neoadjuvant, perioperative and adjuvant approaches, and considers practical aspects of clinical implementation.

The expert

• Prof. Jonathan Spicer, McGill University, Montreal, Canada

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information, visit our website: https://touchrespiratoryime.org/touchexpert-focus-immunotherapy-early-stage-nsclc/

 

Applying immunotherapy in clinical practice for patients with early-stage NSCLC

touchEXPERT FOCUS for touchONCOLOGY

Listen to Prof. Jonathan Spicer share expert insights on immunotherapy in early-stage non-small cell lung cancer (NSCLC). He explores current treatment strategies, highlights the role of neoadjuvant, perioperative and adjuvant approaches, and considers practical aspects of clinical implementation.

The expert

• Prof. Jonathan Spicer, McGill University, Montreal, Canada

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information, visit our website: https://touchoncologyime.org/touchexpert-focus-immunotherapy-early-stage-nsclc/